https://www.selleckchem.com/pr....oducts/favipiravir-t
sible as oral drug carriers of exenatide and have the potential to be extended to other drugs that are not readily oral, such as monoclonal antibodies, vaccines, genes, etc., thus, this would be beneficial for pharmaceutical industries. Further research will focus on the biodistribution of Bio-TMC/HP-55 nanoparticles after oral administration. Metformin, an anti-diabetic drug, has low bioavailability and a short biological half-life. Thus, bioavailability enhancement and prolonged release of the drug are highly desirable. In t
Like
Comment
Share
